CY1123093T1 - Φαρμακοφορο για την επαγωγη του trail - Google Patents

Φαρμακοφορο για την επαγωγη του trail

Info

Publication number
CY1123093T1
CY1123093T1 CY20201100267T CY201100267T CY1123093T1 CY 1123093 T1 CY1123093 T1 CY 1123093T1 CY 20201100267 T CY20201100267 T CY 20201100267T CY 201100267 T CY201100267 T CY 201100267T CY 1123093 T1 CY1123093 T1 CY 1123093T1
Authority
CY
Cyprus
Prior art keywords
trail
imidazolinopyrimidinone
trail gene
compound
inducing pharmaceutical
Prior art date
Application number
CY20201100267T
Other languages
Greek (el)
English (en)
Inventor
Kim D. Janda
Nicholas T. JACOB
Jonathan W. LOCKNER
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of CY1123093T1 publication Critical patent/CY1123093T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20201100267T 2014-03-31 2020-03-20 Φαρμακοφορο για την επαγωγη του trail CY1123093T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461972689P 2014-03-31 2014-03-31
PCT/US2015/023362 WO2015153468A1 (en) 2014-03-31 2015-03-30 Pharmacophore for trail induction

Publications (1)

Publication Number Publication Date
CY1123093T1 true CY1123093T1 (el) 2021-10-29

Family

ID=54241169

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100267T CY1123093T1 (el) 2014-03-31 2020-03-20 Φαρμακοφορο για την επαγωγη του trail

Country Status (20)

Country Link
US (5) US10239877B2 (enExample)
EP (3) EP3662910B1 (enExample)
JP (4) JP6756435B2 (enExample)
KR (2) KR102611067B1 (enExample)
CN (2) CN111499636B (enExample)
AU (4) AU2015241069B2 (enExample)
CA (2) CA2944452C (enExample)
CY (1) CY1123093T1 (enExample)
DK (2) DK3662910T3 (enExample)
ES (2) ES2999685T3 (enExample)
FI (1) FI3662910T3 (enExample)
HR (2) HRP20200478T1 (enExample)
HU (2) HUE069651T2 (enExample)
LT (2) LT3662910T (enExample)
PL (2) PL3125898T3 (enExample)
PT (2) PT3125898T (enExample)
RS (2) RS60163B1 (enExample)
SI (2) SI3125898T1 (enExample)
SM (2) SMT202000219T1 (enExample)
WO (1) WO2015153468A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102438135B1 (ko) 2013-03-13 2022-08-29 온코슈틱스 인코포레이티드 7-벤질-10-(2-메틸벤질)-2,6,7,8,9,10-헥사하이드로이미다조[1,2-a]피리도[4,3-d]피리미딘-5(3h)-온과의 조합 치료요법
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
KR102318238B1 (ko) * 2013-11-15 2021-10-26 온코슈틱스 인코포레이티드 7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조[1,2-a]피리도[3,4-e]피리미딘-5(1H)-온, 이의 염 및 이의 용도
RS60163B1 (sr) 2014-03-31 2020-05-29 Scripps Research Inst Farmakofor koji indukuje trail
LT3805222T (lt) * 2015-01-30 2025-02-10 Oncoceutics, Inc. 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidino-5(1h)-ono dariniai, jų druskos ir jų naudojimas terapijai
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
RS66519B1 (sr) * 2016-01-29 2025-03-31 Oncoceutics Inc Modulacija g protein-spregnutog receptora (gpcr) pomoću imipridona
JP2019527738A (ja) 2016-08-12 2019-10-03 ナンジン ゲイター メディテック カンパニー, リミテッドNanjing Gator Meditech Company, Ltd. プロテインキナーゼ調節剤
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
GB2596010B (en) * 2019-02-11 2023-03-01 Madera Therapeutics Llc Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
WO2020176654A1 (en) 2019-02-27 2020-09-03 Madera Therapeutics, LLC Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
BR112023002082A2 (pt) 2020-08-06 2023-05-09 Eoetvoes Lorand Tudomanyegyetem Síntese de derivados de imipridona e sua avaliação para sua atividade anticancerígena
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN116751199B (zh) * 2023-06-02 2025-03-18 中国科学院基础医学与肿瘤研究所(筹) 一种线粒体蛋白酶靶向嵌合体、制备方法及用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE786028A (fr) * 1971-07-08 1973-01-08 Boehringer Sohn Ingelheim 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
JPS5374893A (en) 1976-12-15 1978-07-03 Fujitsu Ltd Driving method for semiconductor photosensitive device
JPS6132833U (ja) 1984-07-31 1986-02-27 日信工業株式会社 デイスクブレ−キ装置
CA2485343A1 (en) * 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
EP2377534A1 (en) * 2008-06-09 2011-10-19 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
JP2013525308A (ja) * 2010-04-16 2013-06-20 キュリス，インコーポレイテッド Ｋ−ｒａｓ変異を有する癌の治療
WO2012078448A1 (en) * 2010-12-06 2012-06-14 Schering Corporation Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
PE20140890A1 (es) * 2011-03-15 2014-08-05 Chiesi Farma Spa Derivados de isoxazolidina
WO2012138789A2 (en) * 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
SMT202000272T1 (it) 2011-04-29 2020-07-08 Penn State Res Found Induzione del gene trail da parte di cellule normali e tumorali mediante una piccola molecola come terapia anticancro
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
KR102438135B1 (ko) * 2013-03-13 2022-08-29 온코슈틱스 인코포레이티드 7-벤질-10-(2-메틸벤질)-2,6,7,8,9,10-헥사하이드로이미다조[1,2-a]피리도[4,3-d]피리미딘-5(3h)-온과의 조합 치료요법
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9181237B2 (en) * 2013-10-04 2015-11-10 Mallinckrodt Llc Substituted berbines and their synthesis
RS60163B1 (sr) 2014-03-31 2020-05-29 Scripps Research Inst Farmakofor koji indukuje trail

Also Published As

Publication number Publication date
HUE069651T2 (hu) 2025-03-28
JP7688245B2 (ja) 2025-06-04
CA2944452C (en) 2022-07-19
CN111499636B (zh) 2023-01-13
DK3662910T3 (en) 2024-11-04
RS60163B1 (sr) 2020-05-29
US10633385B2 (en) 2020-04-28
EP3125898B1 (en) 2019-12-25
KR102611067B1 (ko) 2023-12-06
SMT202400497T1 (it) 2025-01-14
SI3125898T1 (sl) 2020-07-31
PT3662910T (pt) 2024-11-27
CA3158795A1 (en) 2015-10-08
AU2022283729A1 (en) 2023-02-02
CN111499636A (zh) 2020-08-07
EP3662910A1 (en) 2020-06-10
PT3125898T (pt) 2020-04-01
JP2023022184A (ja) 2023-02-14
EP3662910B1 (en) 2024-09-18
KR20220163533A (ko) 2022-12-09
PL3125898T3 (pl) 2020-11-16
AU2015241069B2 (en) 2020-10-15
FI3662910T3 (fi) 2024-10-31
SMT202000219T1 (it) 2020-05-08
HRP20200478T1 (hr) 2020-07-24
JP2017511321A (ja) 2017-04-20
HRP20241680T1 (hr) 2025-02-28
JP2021119157A (ja) 2021-08-12
AU2015241069A1 (en) 2016-10-20
EP4470617A3 (en) 2025-02-26
ES2779979T3 (es) 2020-08-21
US20200283440A1 (en) 2020-09-10
DK3125898T3 (da) 2020-03-30
JP6873201B2 (ja) 2021-05-19
US20240190877A1 (en) 2024-06-13
JP6756435B2 (ja) 2020-09-16
AU2020286314A1 (en) 2021-01-21
LT3662910T (lt) 2024-12-27
US11891392B2 (en) 2024-02-06
CN106456643A (zh) 2017-02-22
EP3125898A1 (en) 2017-02-08
JP7186256B2 (ja) 2022-12-08
US20190284188A1 (en) 2019-09-19
EP3125898A4 (en) 2017-08-16
US20170107221A1 (en) 2017-04-20
CA2944452A1 (en) 2015-10-08
SI3662910T1 (sl) 2025-05-30
JP2020002170A (ja) 2020-01-09
PL3662910T3 (pl) 2025-08-11
EP4470617A2 (en) 2024-12-04
US20220002300A1 (en) 2022-01-06
KR20160138513A (ko) 2016-12-05
RS66254B1 (sr) 2024-12-31
WO2015153468A1 (en) 2015-10-08
CN106456643B (zh) 2020-04-17
ES2999685T3 (en) 2025-02-26
US10239877B2 (en) 2019-03-26
LT3125898T (lt) 2020-04-10
KR102473930B1 (ko) 2022-12-05
AU2024204977A1 (en) 2024-08-08
HUE049013T2 (hu) 2020-08-28

Similar Documents

Publication Publication Date Title
CY1123093T1 (el) Φαρμακοφορο για την επαγωγη του trail
CY1122909T1 (el) Μεθοδοι αντιμετωπισης της ηωσινοφιλικης οισοφαγιτιδας με χορηγηση αναστολεα του ιl-4r
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1125359T1 (el) Νεα υποκατεστημενα με 6-6 δικυκλικο αρωματικο δακτυλιο νουκλεοσιδικα αναλογα για χρηση ως αναστολεις prmt5
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1123756T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
CY1126855T1 (el) Ενωσεις κυκλικων δινουκλεοτιδιων για τη θεραπευτικη αγωγη καρκινου
CY1125436T1 (el) Αναστολεις dna-pk
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1125245T1 (el) Ετεροκυκλικες ενωσεις ως αναστολεις ρι3κ-γαμμα
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CY1120969T1 (el) Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
CY1123033T1 (el) Σπειροκυκλικοι αναστολεις της καθεψινης c
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
CL2017002994A1 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
CY1119227T1 (el) Παραγωγα πυριδινης ως ηπιοι αναστολεις της rock
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
EA201891317A3 (ru) Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
EP3340916A4 (en) HIGH-DENSITY ELECTRODE MAPPING CATHETER
CY1122364T1 (el) Αναστολεις της ezh2
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων